Can I get colistin without a prescription in the UK?

No. Colistin is a prescription-only medicine (POM) in the UK. Only licensed healthcare professionals can prescribe it, and pharmacists can dispense it only against a valid prescription. This reflects its role as a serious antibiotic reserved for hospital-level infections.

Why is colistin restricted in the UK?

Colistin is restricted because of nephrotoxicity (kidney damage) and neurotoxicity risks, and to prevent resistance development. It's reserved for serious infections caused by multidrug-resistant bacteria where other antibiotics have failed, reflecting antimicrobial stewardship principles.

Is colistin available on the NHS in the UK?

Yes. Colistin is available in NHS hospitals for appropriate infections. It's typically not used in primary care (GP surgeries) and usually requires microbiological confirmation of susceptibility and specialist approval before initiation.

What infections is colistin legally used for in the UK?

Colistin is used for serious hospital-acquired infections caused by multidrug-resistant gram-negative bacteria, including resistant *Pseudomonas aeruginosa*, *Klebsiella*, and *Acinetobacter*. Common indications are hospital-acquired pneumonia, bloodstream infections, and cystic fibrosis-related lung infections.

How does UK colistin regulation compare to other countries?

The UK's approach is similar to Europe and North America: colistin is approved and available but restricted to serious infections to manage resistance and toxicity. Some countries have stricter controls; others are more permissive, reflecting local resistance patterns and clinical practice.

Is Colistin Legal in the UK? Status & Regulations

Yes, colistin is legal in the UK. It's an FDA-approved and EMA-authorised antibiotic used to treat serious bacterial infections, particularly in hospital settings. Colistin has been in clinical use since the 1950s and remains a critical option for multidrug-resistant gram-negative infections. In the UK, it's a prescription-only medicine regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Its legal status reflects its approval through rigorous clinical trials—over 119 clinical studies have evaluated its safety and efficacy. However, access is carefully controlled due to emerging resistance concerns and the antibiotic's potential for nephrotoxicity and neurotoxicity, which means it's typically reserved for serious infections where alternatives have failed.

Colistin's Legal Status in the UK

Colistin is fully legal in the UK and classified as a prescription-only medicine. Its regulatory approval comes via multiple pathways: it's FDA-approved in the United States, EMA-authorised in Europe, and approved by Health Canada. In the UK specifically, the MHRA maintains authorisation for colistin-based medicines, meaning prescribers can legally dispense it under appropriate medical conditions.

The legal framework around colistin reflects its dual nature: it's essential for treating serious infections but requires careful stewardship due to resistance and safety concerns. This balance shapes how UK hospitals and clinicians can legally access and use it.

Historical Context: Why Colistin Matters

Colistin has been in clinical use for over 70 years. It was developed in the 1950s and initially fell out of favour in the 1980s and 1990s when broader-spectrum antibiotics became available. However, the rise of multidrug-resistant (MDR) gram-negative bacteria—particularly Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii—has renewed its clinical importance. Today, colistin is considered a "last-resort" antibiotic for infections that don't respond to other treatments.

This resurgence explains why colistin remains legal and regulated rather than withdrawn: the clinical need is genuine and growing.

UK Regulatory Framework

Colistin in the UK is regulated as a prescription-only medicine (POM). This means:

Prescribing authority: Only licensed healthcare professionals (doctors, dentists, nurse/pharmacist independent prescribers) can legally prescribe colistin.
Pharmacy dispensing: Registered pharmacists can dispense it only against a valid prescription.
Hospital use: UK hospitals can stock and administer colistin under strict protocols, often requiring microbiology and infectious disease input.
Antimicrobial stewardship: The UK's antimicrobial resistance (AMR) strategy encourages restricted use to preserve effectiveness, meaning colistin is typically initiated in secondary care (hospitals) rather than primary care (GP practices).

Clinical Indications in the UK

Colistin is legally used for serious infections caused by multidrug-resistant gram-negative bacteria when other antibiotics are ineffective or contraindicated. Typical UK clinical scenarios include:

Hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) caused by MDR organisms
Bloodstream infections from colistin-susceptible gram-negative bacteria
Urinary tract infections (though less commonly, given alternatives)
Cystic fibrosis-related pulmonary Pseudomonas infections (often administered via inhalation)

Over 119 clinical trials have evaluated colistin's safety and efficacy, providing the evidence base for its continued legal approval.

Safety and Toxicity Considerations

Colistin's legal use is conditional on clinician awareness of its safety profile. The antibiotic carries a risk of:

Nephrotoxicity (kidney damage): Reported in up to 25–50% of treated patients, though modern dosing regimens aim to minimise this.
Neurotoxicity: Includes neuromuscular blockade and encephalopathy, though rare with careful dosing.
Cross-reactivity: Some patients with polymyxin B allergy may react to colistin.

Because of these risks, UK guidance emphasises monitoring renal function and baseline assessment before and during colistin therapy. Prescribers must weigh the serious infection against the toxicity risk—this is why colistin remains a "last-resort" medicine rather than a first-line agent.

Colistin and Antimicrobial Resistance

A key reason colistin's legal use is tightly controlled is the emergence of colistin-resistant gram-negative bacteria. In some regions, resistance rates to colistin in Klebsiella pneumoniae and Acinetobacter have risen significantly. The UK has lower resistance rates than many countries, partly due to antimicrobial stewardship initiatives that restrict colistin use to essential cases.

This legal framework reflects a public health strategy: preserve colistin's effectiveness by limiting exposure and preventing resistance.

Availability and Access in UK Healthcare

Colistin is available in the UK through:

NHS hospitals: Most UK hospital formularies include colistin for serious infections. Access typically requires microbiology confirmation of susceptibility and senior clinical input.
Private healthcare: Private hospitals and clinics can prescribe and dispense colistin under the same regulatory framework.
Specialist centres: Some NHS trusts have centralised colistin protocols, requiring pharmacy and infectious disease approval.

Colistin is not routinely available in primary care (GP surgeries), reflecting its specialist role in treating hospital-level infections.

Comparison with Other Polymyxins

Colistin is one of two polymyxins used clinically. Polymyxin B, its close relative, is also legal in the UK but is less commonly used. Both are reserved for multidrug-resistant gram-negative infections. Colistin is generally preferred because it has a slightly lower incidence of nephrotoxicity at equivalent doses, though this difference is modest.

Related Compounds and Alternatives

In the UK, prescribers may choose colistin or consider alternative approaches to resistant gram-negative infections:

Meropenem: A broad-spectrum beta-lactam often used for resistant infections; lower toxicity profile but variable resistance.
Ceftazidime: A third-generation cephalosporin, sometimes combined with enzyme inhibitors for resistant organisms.
Fluoroquinolones: Such as ciprofloxacin, used for some gram-negative infections but with lower efficacy against Pseudomonas.

Colistin is chosen when these alternatives are ineffective or contraindicated, making it a cornerstone of last-resort therapy.

Future Regulatory Outlook

Colistin's legal status in the UK is unlikely to change substantially in the near term. The antibiotic remains essential, and the regulatory framework is designed to balance access with stewardship. Future developments may include:

Refinements to dosing regimens to reduce nephrotoxicity whilst maintaining efficacy.
Enhanced surveillance for colistin-resistant organisms.
Combination therapies (e.g., colistin with other agents) to improve outcomes and potentially reduce resistance risk.

The UK's participation in EMA and MHRA monitoring systems ensures that if safety concerns emerge or resistance becomes more prevalent, regulatory action can be taken swiftly.

Key Takeaways

Colistin is legal in the UK as a prescription-only medicine approved by the MHRA, FDA, and EMA. It's used for serious infections caused by multidrug-resistant bacteria, particularly in hospital settings. Its legal status reflects both its clinical importance and the need for careful stewardship to manage toxicity risks and prevent resistance. Access is restricted to appropriate clinical scenarios and specialist settings, making it a cornerstone of last-resort antibiotic therapy rather than a routine treatment.